Last reviewed · How we verify
Penehyclidine
At a glance
| Generic name | Penehyclidine |
|---|---|
| Also known as | Chang Tuo Ning |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia (PHASE4)
- Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery (PHASE4)
- Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions (PHASE4)
- Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery (NA)
- Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications (PHASE4)
- Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery
- Penehyclidine for PONV Prophylaxis After Strabismus Surgery (PHASE4)
- Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Penehyclidine CI brief — competitive landscape report
- Penehyclidine updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI